Phase 1-2

Phase 1-2

Inhibrx provides clinical update on ozekibart in late line colorectal cancer

Inhibrx Biosciences, a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates, has released updated interim data from its phase 1/2 study evaluating...
Read more
Phase 1-2

Positive phase 1 data for RAG-17 in amyotrophic lateral sclerosis patients with mutations in the superoxide dismutase 1 gene

Ractigen Therapeutics, a clinical-stage biopharmaceutical company focused on developing next-generation RNA-based medicines, has announced positive preliminary data from the single ascending dose (SAD) phase...
Read more
CRO

New non-compromise early-phase progression accelerator launched

Carbogen AMCIS introduces Sprint for early-phase development, a new, phase-appropriate approach designed to accelerate early-phase progression while maintaining scientific rigour. Sprint has been designed to...
Read more
Phase 1-2

Tenvie doses first subject in phase 1 TNV108 trial for peripheral neuropathies

Tenvie Therapeutics has dosed the first participant in its phase 1 clinical trial of TNV108 to treat peripheral neuropathies. The trial will assess the tolerability...
Read more
Phase 1-2

Dayspring Pharma announces phase 2 trial of CG2001 foam met primary endpoint in Chinese adult men with androgenetic alopecia

Dayspring Pharma has announced top-line data from its phase 2 clinical trial of CG2001 foam in male patients with androgenetic alopecia (AGA). The trial met...
Read more
Phase 1-2

Tenvie doses first subject in phase 1 TNV108 trial for peripheral neuropathies

Tenvie Therapeutics has dosed the first participant in its phase 1 clinical trial of TNV108 to treat peripheral neuropathies. The trial will assess the tolerability...
Read more
Phase 1-2

Preliminary AMT-191 phase 1/2a data shows sustained increases in α-Gal A enzyme activity in patients with Fabry Disease

uniQure has announced updated preliminary safety and exploratory efficacy data from 11 patients in its phase 1/2a trial of AMT-191, an investigational AAV gene therapy...
Read more
Phase 1-2

Positive longer-term phase 1 data of Nexiguran Ziclumeran (nex-z) in patients with Transthyretin Amyloidosis with cardiomyopathy

Intellia Therapeutics, a leading clinical-stage gene editing company focused on revolutionising medicine with CRISPR-based therapies, has announced positive follow-up data from the ongoing phase 1 clinical...
Read more
- Advertisement -spot_img
- Advertisement -
EPO Summit ad
- Advertisement -
Pharmconex ad
- Advertisement -
NLS Days ad
- Advertisement -
ILMAC ad
- Advertisement -
BIO Europe

Latest posts

Load more

Drug Discovery & Development (DDD) is dedicated to advancing scientific innovations into active medical solutions. Its aim is to accelerate breakthroughs in medicine, addressing human disease and improving global health outcomes.

Menu

© Web design by Social Media Services 2026. All rights reserved.